Dman SE, Park DS, Cohen AW, Cheung MW, Chandra M, Shirani J. Caveolin3 knockout mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem 2002; 277: 3898897. Park DS, Woodman SE, Schubert W, Cohen AW, Frank PG, Chandra M. Caveolin 1/3 double knockout mice are viable but lack both muscle and nonmuscle caveolae and develop a severe cardiomyopathic phenotype. Am J Pathol 2002; 160: 220717. Murata T, Lin MI, Huang Y, Yu J, Bauer PM, Giordano FJ, Sessa WC. Re15 pgdh Inhibitors products expression of caveolin1 in endothelium rescues the vascular, cardiac, and pulmonary defects in worldwide caveolin1 knockout mice. J Exp Med 2007; 204(ten): 237382. Wunderlich C, Schober K, Lange SA, et al. Disruption of caveolin1 leads to enhanced nitrosative anxiety and extreme systolic and diastolic heart failure. Biochem Biophys Res Commun 2006; 340(two): 7028. Wang W, Schulze CJ, SuarezPinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002; 106: 154349. Sawicki H, Leon H, Sawicka J, et al. Degradation of myosin light chain in isolated rat hearts subjected to ischemiareperfusion injury: a new intracellular target for matrix metalloproteinase2. Circulation 2005; 112: 54452. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 56273. Puyraimond A, Fridman R, Lemesle M, Arbeille B, Menashi S. MMP2 colocalizes with caveolae on the surface of endothelial cells, Exp Cell Res 2001; 262: 2836. Atkinson SJ, English JL, Holway N, Murphy G. Cellular cholesterol regulates MT1 MMP dependent activation of MMP 2 by means of MEK1 in HT1080 fibrosarcoma cells. FEBS Lett 2004; 566: 6570. Fiucci G, Ravid D, Reich R, Liscovitch M. Caveolin1 inhibits anchorageindependent growth, anoikis and invasiveness in MCF7 human breast cancer cells. Oncogene 2002; 21: 236575. Woodman SE, Park DS, Cohen AW, et al. Caveolin3 knockout mice create a progressive cardiomyopathy and show hyperactivation on the p42/44 MAPK cascade. J Biol Chem 2002; 277(41): 3898897. Capozza F, Cohen AW, Cheung MW, et al. Musclespecific interaction of caveolin isoforms: differential complicated formation between caveolins in fibroblastic vs. muscle cells. Am J Physiol Cell Physiol 2005; 288: C677C691. Song KS, Scherer PE, Tang Z, et al. Expression of caveolin3 in skeletal, cardiac, and smooth muscle cells. Caveolin3 is usually a component from the sarcolemma and cofractionates with dystrophin and dystrophinassociated glycoproteins. J Biol Chem 1996; 271: 151605. Crosbie RH, Yamada H, Venzke DP, et al. Caveolin3 will not be an integral component in the dystrophin glycoprotein complex. FEBS Lett 1998; 427: 27982. Sotgia F, Lee JK, Das K, et al. Caveolin3 directly interacts together with the Cterminal tail of betadystroglycan. Identification of a central WWlike domain inside caveolin family members members. J Biol Chem 2000; 275: 3804858. GarciaCardena G, Fan R, Stern DF, et al. Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin1. J Biol Chem 1996; 271: 2723740. Smythe GM, Eby JC, Disatnik MH, et al. A caveolin3 mutant that causes limb girdle muscular dystrophy sort 1C disrupts Src localization and activity and induces apoptosis in skeletal myotubes. J Cell Sci 2003; 116(Aspect 23): 473949. Sotgia F, Bonuccelli G, Minetti C, et al. Phosphofructokinase musclespecific isoform demands caveolin3 expression for plasmaDas and.
